Rheumatoid Arthritis (RA)NCT07525856
Acceptability of a Nurse-led Telehealth Remote Self-monitoring Model of Care in Patients With Rheumatoid Arthritis
A study testing Nurse-led telehealth remote self-monitoring in people with Rheumatoid Arthritis (RA), run by CHU de Quebec-Universite Laval at 4 sites in Canada.
Trial summary
Canada urgently needs new ways to provide rheumatology care that improve treatment and make it easier for people to get high-quality care. E-health technology is a new and promising way to do this, but it hasn't been studied much yet in rheumatology. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Rheumatoid Arthritis (RA)
- What is being tested?
- Nurse-led telehealth remote self-monitoring
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 104 participants
- Where
- 4 sitesCanada
- Study dates
- Jan 2027to Jun 2028
- Phase
- Interventional
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Age ≥ 18 years
- Diagnosis of rheumatoid arthritis (RA) according to the ACR 2010 criteria
- Disease duration ≥ six months
- Who experienced a flare defined by an increase of the clinical disease activity index (CDAI) ≥ 4.5 or a DMARDs switch or addition within the preceding three months
- Understanding French or English
Who cannot join
- Inability to consent
- Inability to complete questionnaires
- No Internet access
Trial locations and contacts
4 sites in 1 country. Contact the study team or a site near you to ask about taking part.
Canada4 sites
Hopital general de Montreal
Montreal, Quebec, H3H 1V6
Ines Colmegna, MD, +1 (514) 934-1934 ext. 35639, ines.colmegna@mcgill.ca
Ines Colmegna, MD
Centre de l'ostéporose et de rhumatologie de Québec
Québec, Quebec, G1V 2M1
Louis Bessette, MD, +1 418-650-0698, louis.bessette@crchudequebec.ulaval.ca
Louis Bessette, MD, + 1 418-650-0698, louis.bessette@crchudequebec.ulaval.ca
CHU de Quebec-Universite Laval
Québec, Quebec, G1V4G2
Laetitia Michou, MD PhD, +14185254444 ext. 48383, laetitia.michou@crchudequebec.ulaval.ca
Laetitia Michou, MD PhD
Hopital Fleurimont et Hotel Dieu de Sherbrooke
Sherbrooke, Quebec, J1H 5H3
Hugues Allard-Chamard, MD, +1 819 821-8000 ext. 15261, hugues.allard-chamard@usherbrooke.ca
Hugues Allard-Chamard, MD
About this study
Official title: Acceptability of a Nurse-led Telehealth Remote Self-monitoring Model of Care in Patients With Rheumatoid Arthritis, a Multicentre Randomized Pilot Study
Canada urgently needs new ways to provide rheumatology care that improve treatment and make it easier for people to get high-quality care. E-health technology is a new and promising way to do this, but it hasn't been studied much yet in rheumatology.
The investigators will test a new way to help people with rheumatoid arthritis at four clinics in Quebec. This study will check if the new approach is easy to use, fits well into the clinics' daily routine, and if both patients and healthcare workers find it helpful and acceptable.
Read more
This new approach involves nurses helping patients check their own health from home using an online platform.
104 adults who have rheumatoid arthritis and who have had a flare-up or a change in their medication in the last three months, will participate. Some will start using the online self-monitoring tool right away for 16 months, while others will continue with their usual care for 8 months before trying the tool. During the time they use the tool, they will fill out monthly online questionnaires to check their health. A rheumatology nurse will review their answers, suggest any needed care, provide personalized health information, and be available to answer questions through messages.
This new way of care, where nurses help patients monitor their rheumatoid arthritis from home, helps make better use of limited specialist time. It's more convenient for patients, especially those who live far away, and helps meet their needs between regular doctor visits while keeping the quality of care high.
Read the detailed description
Background: Limited access to rheumatologists in Canadian remote regions leads to delays in new-onset rheumatoid arthritis (RA) diagnosis and inadequate follow-up for disease flares or treatment adjustments. There is a critical need for innovative models of care addressing these unmet needs in resource-limited settings. E-health technologies offer a promising solution by bridging the gap between in-person rheumatology appointments. These tools can optimize the use of scarce specialist resources, enhance the continuity and quality of care, and provide greater convenience for patients-particularly in underserved or geographically isolated areas. By supporting timely interventions and patient-centered monitoring, e-health can play a vital role in improving outcomes and ensuring equitable access to care.
Objectives: This study will evaluate the acceptability and feasibility of a nurse-led telehealth remote self-monitoring model of care for patients with RA.
Primary Objective: Acceptability of a nurse-led telehealth remote self-monitoring program, defined as patient-reported perceptions of usefulness, ease of use, attitudes, and overall experience, and assessed with questionnaires and semi-structured interviews.
Secondary Objectives: Feasibility using the RE-AIM implementation framework:
- Reach: Proportion of eligible patients enrolled and comparison of participant versus non-participant characteristics.
- Effectiveness: Frequency and relevance of nurse calls, healthcare utilization, health-related quality of life, disease activity, and medication adherence.
- Adoption: Completion rate of remote monitoring questionnaires, study retention, and reasons for discontinuation.
- Implementation: Fidelity to protocol, appropriateness of alerts, subsequent actions, and timeliness of in-person visits; identify barriers and facilitators.
- Maintenance: Intention for continued use among healthcare providers and patients.
Methods - The investigators will recruit 104 adults with RA who experienced a flare or required a DMARDs switch within the preceding three months, from 4 rheumatology practices (community and academic sites) providing care to >15,000 RA patients. All participants will be randomized 1:1 to receive either immediate intervention (for 16 months) or delayed, i.e. usual care for 8 months (control period) followed by 8 months of intervention, consisting of remote self-monitoring using a web platform co-developed with patients, rheumatologists, and nurses. Rheumatology visits will be scheduled every 3-6 months, with additional visits as necessary. The intervention includes nurse-led remote self-monitoring of RA, with patients completing monthly self-assessments of disease activity (RADAI), symptoms and function (PROMIS-29). Rheumatology nurses will receive alerts if monitoring suggests moderate/high disease activity and will contact participants to determine care needed. Tailored information based on PROMIS-29 answers will be sent to facilitate self-management. Asynchronous messaging with rheumatology nurses and information on RA self-management will be available. Data will be collected using questionnaires and semi-structured interviews. Analysis will use quantitative (generalized linear mixed-effect models comparing within group changes [8 months - baseline, both groups combined] and between groups differences [intervention versus control] in continuous variables), and qualitative methods (thematic content analysis by two independent researchers).
Impact and feasibility. A nurse-led remote self-monitoring of RA using a web-based platform codeveloped with patient input, has potential to enhance access to care and more efficiently use scarce rheumatology resources while providing high quality care.
- Conditions
- Rheumatoid Arthritis (RA)
- Being tested
- Nurse-led telehealth remote self-monitoring
- Keywords
- Arthritis activity remote self-monitoring, Nurse-led telehealth intervention, Pilot randomised trial, Self-assessment of disease activity, RE-AIM implementation framework, Semi-structured interviews
- Medical subject headings
- Arthritis, Rheumatoid
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Nurse-led telehealth remote self-monitoringOther
Remote self-monitoring will use a web platform co-developed with patients, rheumatologists, and nurses. The intervention includes nurse-led remote self-monitoring of RA, with patients completing monthly self-assessments of disease activity (RADAI), symptoms and function (PROMIS-29). Rheumatology nurses will receive alerts if monitoring suggests moderate/high disease activity and will contact participants to determine care needed. Tailored information based on PROMIS-29 answers will be sent to facilitate self-management. Asynchronous messaging with rheumatology nurses and information on RA self-management will be available.
| Study group | Role | What they receive |
|---|---|---|
| Immediate intervention (for 16 months) | Experimental | The intervention includes nurse-led remote self-monitoring of RA, with patients completing monthly self-assessments of disease activity (RADAI), symptoms and function (PROMIS-29). Rheumatology nurses will receive alerts if monitoring suggests moderate/high disease activity and will contact participants to determine care needed. Tailored information based on PROMIS-29 answers will be sent to facilitate self-management. Asynchronous messaging with rheumatology nurses and information on RA self-management will be available. Receives: Other: Nurse-led telehealth remote self-monitoring |
| Delayed intervention ( 8 months of control period followed by 8 months with the intervention) | Active comparator | Usual care for 8 months, consisting in rheumatology visits scheduled every 3-6 months.
Followed by the intervention for 8 months: The intervention includes nurse-led remote self-monitoring of RA, with patients completing monthly self-assessments of disease activity (RADAI), symptoms and function (PROMIS-29). Rheumatology nurses will receive alerts if monitoring suggests moderate/high disease activity and will contact participants to determine care needed. Tailored information based on PROMIS-29 answers will be sent to facilitate self-management. Asynchronous messaging with rheumatology nurses and information on RA self-management will be available. Receives: Other: Nurse-led telehealth remote self-monitoring |
What is being measured
The primary outcome is the main question the study is designed to answer.
Acceptability of the intervention evaluated by a questionnaire
The questionnaire of patients' perceived usefulness and ease of use of the remote self-monitoring web platform will be completed by participants at 16 months, rated using a 13-item questionnaire utilizing five-point Likert scales.
Measured: At 16 months
Acceptability of the intervention evaluated by a qualitative analysis
Semi-structured interviews with patients and providers will be completed with a purposive sample of participants (diverse with respect to age, gender, ethnicity, education, disease type and duration, employment, urban/rural) at study end. Participants will meet in groups of 8-12 for 60-90 minutes; groups will continue until saturation of themes is obtained (estimated to be 2-3 groups). Topics will include perceived acceptability, convenience, satisfaction, beliefs, perceived usefulness and ease of use, how care received met patient needs, barriers and enablers to adopting this new model of care.
Measured: At 16 months
Secondary outcomes (15)
Age category of eligible participants
Age category of eligible patients
Measured: Until the end of recruiting period
Frequency of calls to nurses
Frequency of calls to nurses will be collected on the electronic medical record of each rheumatology clinic
Measured: Up to the end of intervention at 16 months
Use of other health care services
Self-reported by patients in a survey administered every three months, including emergency room visits, hospitalizations, visits to primary care physicians, other specialists, other healthcare professionals.
Measured: Every 3 months over 16 months
Health-related quality of life evaluated by the Patient-Reported Outcomes Measurement Information System-29 questionnaire
Measured by the Patient-Reported Outcomes Measurement Information System-29 (PROMIS-29) which is a patient-reported measure of symptoms and function validated in French, which includes four items from each of seven domains (physical function, depression, anxiety, fatigue, sleep disturbances and ability to participate in social roles and activities, pain interference) and a single item on pain intensity. It has been co-developed with patients and validated in rheumatic diseases. Each item has five response options, except for pain which has eleven. A total score is calculated for each domain from the sum of item answers. Range from 20 to 80.
Measured: Every 3 months over 16 months
Disease activity evaluated by the Clinical Disease Activity Index
Measured using Clinical Disease Activity Index (CDAI) at every 3-6 months rheumatology follow-up visit The CDAI is the sum of the count of swollen/tender joint count of 28 joints and patient and physician global assessment on VAS (0-10 cm) Scale for estimating disease activity. The CDAI has range from 0 to 76.
Measured: Every 3 to 6 months over 16 months
Proportion of medication adherence
The proportion of adherence will be calculated by dividing the quantity received by the quantity prescribed for each month starting three months before enrollment until six months after. The mean proportion of adherence per medication will be calculated for each time period by taking the mean of all months included in each of the periods. For each of these periods, the patient will be considered adherent if the mean is greater or equal to 80%.
Measured: Every 3 months up to the end of intervention over 16 months
Completion rate of patient questionnaires for remote self-monitoring
Completion rate of patient questionnaires for remote self-monitoring (Rheumatoid Arthritis Disease Activity Index RADAI and Patient-Reported Outcomes Measurement Information System-29, PROMIS-29)
Measured: Every month during the intervention over 16 months
Proportion of participants still connecting to the web platform at study end
Proportion of participants still connecting to the web platform at study end
Measured: At 16 months
Time spent on the web platform
Time spent on the web platform by each participant
Measured: Up to the end of intervention at 16 months
Measuring the number of alerts per patient
Measuring the number of alerts per patient
Measured: Up to the end of intervention at 16 months
Questionnaire for the evaluation of health professionals' acceptance of a new telemonitoring system
Rheumatology nurses, rheumatologists, and administrative staff will answer the questionnaire for the evaluation of health professionals' acceptance of a new telemonitoring system, a 33-item anonymous survey on their intended sustained use of nurse-led remote self-monitoring with a 7-point likert scale for each questions.
Measured: At 16 months
Sex category of eligible patients
Sex category of eligible patients
Measured: Up to the end of recruiting period
Clinical appropriateness of alerts
Clinical appropriateness of alerts based on rheumatology team subsequent actions (ex: timeliness of in-person visits, whether triggered visits led to medication change)
Measured: Up to the end of intervention over 16 months
Number of nurse-patient interactions
Number of nurse-patient interactions using the platform
Measured: Up to the end of intervention over 16 months
Reason for nurse calls
Reason for nurse calls will be collected on the electronic medical record of each rheumatology clinic
Measured: Up to the end of intervention at 16 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted13 Apr 2026
- Study startJan 2027 (estimated)
- Primary completionMay 2028 (estimated)
- Study completionJun 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Rheumatoid Arthritis (RA)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- One arm with immediate intervention for 16 months; and one arm with delayed intervention, i.e. usual care for 8 months (control period) followed by 8 months of intervention
- Masking
- None (open label)
- Enrolment
- 104 participants (estimated)
Sponsor and investigators
- Lead sponsor
- CHU de Quebec-Universite Laval
- Sponsor type
- University, hospital or other
- Collaborators
- The Arthritis Society, Canada
- Responsible party
- Sponsor
- Investigators
- Laetitia Michou, MD PhD, Principal investigator, CHU de Quebec-Universite Laval
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07525856
- Sponsor's protocol ID
- 2026-8556
- Status last verified
- Oct 2026
- First submitted
- 25 Mar 2026
- Last updated
- 22 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided